- Home
- TLSA vs CTOR Comparison
TLSA vs CTOR Comparison
Compare TLSA & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CTOR
- Stock Information
- Founded
- TLSA 2013
- CTOR 2021
- Country
- TLSA United Kingdom
- CTOR United States
- Employees
- TLSA N/A
- CTOR N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- TLSA Health Care
- CTOR
- Exchange
- TLSA Nasdaq
- CTOR NYSE
- Market Cap
- TLSA 187.0M
- CTOR 63.7M
- IPO Year
- TLSA 2000
- CTOR N/A
- Fundamental
- Price
- TLSA $1.50
- CTOR $5.30
- Analyst Decision
- TLSA
- CTOR Buy
- Analyst Count
- TLSA 0
- CTOR 2
- Target Price
- TLSA N/A
- CTOR $6.00
- AVG Volume (30 Days)
- TLSA 260.9K
- CTOR 3.3M
- Earning Date
- TLSA 07-15-2025
- CTOR 08-11-2025
- Dividend Yield
- TLSA N/A
- CTOR N/A
- EPS Growth
- TLSA N/A
- CTOR N/A
- EPS
- TLSA N/A
- CTOR N/A
- Revenue
- TLSA N/A
- CTOR N/A
- Revenue This Year
- TLSA N/A
- CTOR N/A
- Revenue Next Year
- TLSA N/A
- CTOR N/A
- P/E Ratio
- TLSA N/A
- CTOR N/A
- Revenue Growth
- TLSA N/A
- CTOR N/A
- 52 Week Low
- TLSA $0.63
- CTOR $0.55
- 52 Week High
- TLSA $1.91
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- TLSA 48.99
- CTOR N/A
- Support Level
- TLSA $1.53
- CTOR N/A
- Resistance Level
- TLSA $1.81
- CTOR N/A
- Average True Range (ATR)
- TLSA 0.11
- CTOR 0.00
- MACD
- TLSA -0.01
- CTOR 0.00
- Stochastic Oscillator
- TLSA 11.76
- CTOR 0.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.